Shandong Weigao Group Medical Polymer Förvaltning

Förvaltning kriterier kontrolleras 3/4

Vi har för närvarande inte tillräcklig information om VD:n.

Viktig information

Rinan Cong

Verkställande direktör

CN¥4.0m

Total ersättning

VD-lön i procent	42.1%
Anställning som VD	no data
Ägande av VD	0.05%
Ledningens genomsnittliga anställningstid	2.8yrs
Styrelsens genomsnittliga mandatperiod	2.8yrs

Senaste uppdateringar av ledningen

Recent updates

Analys av ersättningar till VD

Hur har Rinan Cong:s ersättning förändrats jämfört med Shandong Weigao Group Medical Polymer:s resultat?
Datum	Total ersättning	Lön	Företagets resultat
Jun 30 2024	n/a	n/a	CN¥2b
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	CN¥4m	CN¥2m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥3b
Dec 31 2022	CN¥5m	CN¥950k	CN¥3b
Sep 30 2022	n/a	n/a	CN¥3b
Jun 30 2022	n/a	n/a	CN¥3b
Mar 31 2022	n/a	n/a	CN¥2b
Dec 31 2021	CN¥3m	CN¥903k	CN¥2b

Ersättning vs marknad: Rinan s total kompensation ($USD 549.70K ) är ungefär genomsnittet för företag av liknande storlek på Hong Kong marknaden ($USD 674.52K ).

Ersättning vs inkomst: Ersättningen från Rinan har varit i linje med företagets resultat under det senaste året.

VD OCH KONCERNCHEF

Rinan Cong (43 yo)

no data

Anställning

CN¥3,990,000

Kompensation

Mr. Rinan Cong served as Chief Executive Officer at Shandong Weigao Group Medical Polymer Company Limited since March 30, 2021 until 2024 and served as Executive Director since May 24, 2021 until 2024 and...

Ledningsgrupp

Namn	Position	Anställning	Kompensation	Ägarskap
Jing Long	Executive Chairman of the Board & Compliance Officer	6.3yrs	CN¥8.27m	0.14% HK$ 32.9m
Rinan Cong	Chief Executive Officer	no data	CN¥3.99m	0.048% HK$ 11.2m
Junqiang Lu	Executive Director	2.8yrs	CN¥1.32m	inga uppgifter
Xue Feng Wu	Chief Financial Officer	8.1yrs	inga uppgifter	inga uppgifter
Xia Yan	Non-Executive Director	less than a year	inga uppgifter	inga uppgifter
Daoming Wang	Executive Director	less than a year	inga uppgifter	0.011% HK$ 2.5m
Miu Ling Wong	Company Secretary	18.8yrs	inga uppgifter	inga uppgifter

2.8yrs

Genomsnittlig anställningstid

49yo

Genomsnittlig ålder

Erfaren ledning: 1066 s ledningsgrupp anses vara erfaren ( 2.8 års genomsnittlig anställningstid).

Styrelseledamöter

Namn	Position	Anställning	Kompensation	Ägarskap
Jing Long	Executive Chairman of the Board & Compliance Officer	6.3yrs	CN¥8.27m	0.14% HK$ 32.9m
Junqiang Lu	Executive Director	2.8yrs	CN¥1.32m	inga uppgifter
Xia Yan	Non-Executive Director	less than a year	inga uppgifter	inga uppgifter
Daoming Wang	Executive Director	less than a year	inga uppgifter	0.011% HK$ 2.5m
Lin Chen	Non-Executive Director	4yrs	inga uppgifter	inga uppgifter
Hong Meng	Independent Non-Executive Director	2.5yrs	CN¥150.00k	inga uppgifter
Guohui Li	Independent Non-Executive Director	2.8yrs	CN¥207.00k	inga uppgifter
Zhengpeng Tang	Vice Chairman	4yrs	inga uppgifter	inga uppgifter
Meijun Gu	Chairman of the Supervisors	4.7yrs	inga uppgifter	inga uppgifter
Zhuangqiu Zhang	Employee Representative Supervisor	2.9yrs	inga uppgifter	inga uppgifter
Qiang Li	Independent Non-Executive Director	2.3yrs	CN¥150.00k	inga uppgifter
Heng Sun	Independent Non-Executive Director	less than a year	inga uppgifter	inga uppgifter

2.8yrs

Genomsnittlig anställningstid

49yo

Genomsnittlig ålder

Erfaren styrelse: 1066 s styrelse anses inte vara erfaren ( 2.8 års genomsnittlig mandatperiod), vilket föreslår en ny styrelse.

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2025/03/25 10:20
Aktiekurs vid dagens slut	2025/03/25 00:00
Intäkter	2024/06/30
Årlig intjäning	2023/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Shandong Weigao Group Medical Polymer Company Limited bevakas av 36 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Jason Mann	Barclays
Derrick Sun	BNP Paribas Securities (Asia)
Jessica Li	BofA Global Research

Shandong Weigao Group Medical Polymer Förvaltning

Förvaltning kriterier kontrolleras 3/4

Viktig information

Senaste uppdateringar av ledningen

Shandong Weigao Group Medical Polymer Company Limited Approves Board Appointments

Shandong Weigao Group Medical Polymer Company Limited, Annual General Meeting, May 28, 2024

Shandong Weigao Group Medical Polymer Company Limited Announces the Resignation of Ni Has Tendered as Executive Director, Effective from 31 December 2023

Shandong Weigao Group Medical Polymer Company Limited Appoints Li Qiang as an Independent Non-Executive Director

Key Executive recently sold HK$5.8m worth of stock

Less than half of directors are independent

Recent updates

Shandong Weigao Group Medical Polymer Company Limited to Report Fiscal Year 2024 Results on Mar 26, 2025

Shandong Weigao Group Medical Polymer Company Limited Approves the Distribution of Interim Dividend for the Six Months Ended 30 June 2024, Payable on 22 November 2024

Investor sentiment deteriorates as stock falls 17%

Upcoming dividend of CN¥0.092 per share

Investor sentiment improves as stock rises 16%

First half dividend of CN¥0.092 announced

First half 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.27 in 1H 2023)

Shandong Weigao Group Medical Polymer Company Limited Proposes an Interim Dividend for the Six Months Ended 30 June 2024, Payable on Before 22 November 2024

Shandong Weigao Group Medical Polymer Company Limited to Report First Half, 2024 Results on Aug 28, 2024

Shandong Weigao Group Medical Polymer Company Limited Approves Board Appointments

Upcoming dividend of CN¥0.094 per share

Full year 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.61 in FY 2022)

Final dividend of CN¥0.094 announced

Shandong Weigao Group Medical Polymer Company Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.60 in FY 2022)

Shandong Weigao Group Medical Polymer Company Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 July 2024

Shandong Weigao Group Medical Polymer Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Shandong Weigao Group Medical Polymer Company Limited Provides Earnings Guidance for the Year Ended 31 December 2023

Investor sentiment deteriorates as stock falls 18%

Shandong Weigao Group Medical Polymer Company Limited Announces the Resignation of Ni Has Tendered as Executive Director, Effective from 31 December 2023

Shandong Weigao Group Medical Polymer Company Limited Approves Distribution of Interim Dividend for the Six Months Ended 30 June 2023

Upcoming dividend of CN¥0.073 per share at 2.4% yield

First half 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.34 in 1H 2022)

Shandong Weigao Group Medical Polymer Company Limited Proposes Interim Dividend for the Six Months Ended 30 June 2023, Payable on 24 November 2023

Shandong Weigao Group Medical Polymer Company Limited to Report First Half, 2023 Results on Aug 29, 2023

Now 21% undervalued after recent price drop

Shandong Weigao Group Medical Polymer Company Limited Approves Final Dividend for the Year Ended 31 December 2022, Payable on or Before 14 July 2023

Upcoming dividend of CN¥0.079 per share at 1.5% yield

Full year 2022 earnings released: EPS: CN¥0.60 (vs CN¥0.51 in FY 2021)

Shandong Weigao Group Medical Polymer Company Limited Appoints Li Qiang as an Independent Non-Executive Director

Key Executive recently sold HK$5.8m worth of stock

Now 22% undervalued

Less than half of directors are independent

Shandong Weigao Group Medical Polymer Company Limited Announces Resignation of Wang Jinxia as an Independent Non-Executive Director of the Company, A Member of Audit Committee, A Member of Remuneration Committee, A Member of Nomination Committee and A Member of Corporate Governance Committee

Now 20% undervalued

Shandong Weigao Group Medical Polymer Company Limited Approves Interim Dividend for the Six Months Ended June 30, 2022, Payable on November 11, 2022

Upcoming dividend of CN¥0.086 per share

Shandong Weigao Group Medical Polymer Company Limited (SEHK:1066) agreed to acquire Weihai Weigao Medical Materials Company Limited from Weigao Holding Company Limited for approximately RMB288.0 million.

First half 2022 earnings released: EPS: CN¥0.32 (vs CN¥0.27 in 1H 2021)

Shandong Weigao Group Medical Polymer Company Limited Announces Executive Changes

Shandong Weigao Group Medical Polymer Company Limited to Report First Half, 2022 Results on Aug 22, 2022

Investor sentiment improved over the past week

Shandong Weigao Group Medical Polymer Company Limited Approves Executive Appointments

Upcoming dividend of CN¥0.065 per share

Now 22% undervalued after recent price drop

Full year 2021 earnings released: EPS: CN¥0.50 (vs CN¥0.47 in FY 2020)

Less than half of directors are independent

Shandong Weigao Group Medical Polymer Company Limited Announces Executive Resignations

Shandong Weigao Group Medical Polymer Company Limited, Annual General Meeting, Jun 06, 2022

Full year 2021 earnings released: EPS: CN¥0.50 (vs CN¥0.45 in FY 2020)

Shandong Weigao Group Medical Polymer Company Limited Recommends Final Dividend for the Year Ended December 31, 2021

Investor sentiment improved over the past week

Shandong Weigao Group Medical Polymer Company Limited to Report Q4, 2021 Results on Mar 29, 2022

Upcoming dividend of CN¥0.077 per share

First half 2021 earnings released: EPS CN¥0.27 (vs CN¥0.22 in 1H 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Shandong Weigao Group Medical Polymer Company Limited Approves Final Dividend for the Year Ended December 31, 2020 At the Annual General Meeting Held on May 24, 2021

Upcoming dividend of CN¥0.068 per share

Full year 2020 earnings released: EPS CN¥0.45 (vs CN¥0.41 in FY 2019)

Chairman & Compliance Officer Hua Wei Zhang has left the company

Executive Vice Chairman Yi Wang has left the company

Shandong Weigao Group Medical Polymer Company Limited Approves the Appointment of Tang Zheng Peng as a Non-Executive Director of the Company

New 90-day low: HK$13.28

Shandong Weigao Group Medical Polymer Company Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Chairman & Compliance Officer recently sold HK$14m worth of stock

New 90-day high: HK$17.06

Shandong Weigao Group Medical Polymer Company Limited Announces Director Changes

New 90-day low: HK$14.22